期刊文献+

甲醛固定的H22细胞联合IL-2抑制小鼠H22肝癌生长效果观察 被引量:2

下载PDF
导出
摘要 目的观察甲醛固定的H22肿瘤细胞联合IL-2对小鼠H22肝癌细胞腹部移植瘤生长的影响。方法20只小鼠,均采用股部皮下1×105个H22细胞的方法建立小鼠H22肝癌皮下移植瘤模型。将其随机分为A、B、C、D组,各5只。肿瘤直径超过1 cm后A、B、C、D组分别瘤内注射生理盐水、甲醛固定H22细胞、IL-2、甲醛固定H22细胞+IL-2各0.5 mL。H22细胞浓度为106/mL,IL-2浓度为8×103IU/mL。每3d注射1次,共注射4次。治疗结束处死动物,取瘤称重,并计算抑瘤率。采用免疫组化SABC法对肿瘤组织染色,光景下观察瘤内CD8+T淋巴细胞表达情况。结果 A、B、C、D组肿瘤治疗后质量分别为(6.683±1.102)g、(2.851±0.223)g、(2.282±0.443)g、(1.052±0.225)g,B、C、D组与A组相比明显降低,D组与B、C组相比明显降低(P均<0.05)。B、C、D组抑瘤率分别为51.58%、60.54%、80.96%。D组小鼠瘤体内大量肿瘤细胞变性和坏死,且瘤内有大量CD8+T淋巴细胞浸润,阳性产物主要呈现在细胞膜上并被染成棕褐色。B、C组内仅见少量CD8+T淋巴细胞。结论甲醛固定的H22细胞联合IL-2具有延迟荷瘤小鼠H22肝癌形成,限制生长的作用。
出处 《山东医药》 CAS 2012年第38期23-24,共2页 Shandong Medical Journal
  • 相关文献

参考文献12

  • 1Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy [ J ]. Cancer Immunol Immunother, 2004, 53 (3) :240-248.
  • 2AH Lau, AW Thomson. Dendritic cells and immune regulation in the liver[J]. Gut, 2003,52(2) :307-331.
  • 3Ohno T. Autologous cancer vaccine : a novel formulation [ J ]. Mi- erobiol Immunol, 2003,47 ( 4 ) :255-263.
  • 4Tartour E, Mehtali M, Sastre-Garau X, et al. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings [ J ]. Br J Cancer, 2000,83 ( 11 ) : 1454-1461.
  • 5Liu SQ, Saijo K, Todoroki T, et al. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour section [ J ]. Nature Medicine, 1995,1 ( 3 ) :267-271.
  • 6Banchereau J, Steinman RM. Dendritic cells and the control of im- munity [ J ]. Nature, 1998,392 (6673) :245-252.
  • 7Armstrong AC, Eaton D, Ewing JC. Science, medicine, and the future [ J ]. BMJ, 2002,323 ( 7324 ) : 1289-1293.
  • 8I Horiuchi K, Tsurushima H, Kim BS, et al. Expansion of human autologous eytotoxie T lymphoeytes on fixed target tumor cells [ J ]. Cytoteehnology, 1998,26(2) :119-124.
  • 9邱继刚,邱双健,吴志全.肿瘤患者的免疫状态指标[J].世界华人消化杂志,2004,12(6):1427-1431. 被引量:4
  • 10O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer[ J ]. Blood, 2004, 104 ( 8 ) :2235-2243.

二级参考文献49

  • 1Juan Zhang~1 Jin-Kun Zhang~2 Shao-Hong Zhuo~3 Hai-Bin Chen~2 1 Clinical Laboratory,The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,Guangdong Province,China2 Cancer Pathology Laboratory,Shantou University Medical College,Shantou 515031,Guangdong Province,China3 Department of Gastroenterology,Third Municipal Hospital of Shantou,Shantou 515073,Guangdong Province,China.Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells[J].World Journal of Gastroenterology,2001,7(5):690-694. 被引量:26
  • 2Yamazaki K, Yano T, Kameyama T, Suemitsu R, Yoshino I,Sugio K. Clinical significance of serum TH1/TH2 cytokines in patients with pulmonary adenocarcinoma. Surgery 2002;131(Suppl 1): S236-S241.
  • 3Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP,Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM,.Kwok WW, Storkus WJ. Disease-associated bias in T helper type 1 (Thl)/Th2 CD4(+) T cell responses, against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-628.
  • 4Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A.CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-1099.
  • 5Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V,Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761.
  • 6Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjorge L,Butzow R, Zipfel PF, Meri S. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumor cells. Br J Cancer 2002;87:1119-1127.
  • 7Durrant LG, Spendlove I. Immunization against tumor cell surface complement-regulatory proteins. Curr Opin Investig Drugs 2001;2:959-966.
  • 8Kuhn DJ, Smith DM, Pross S, Whiteside TL, Dou QP.Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochern 2003;89:824-836.
  • 9Fujiwara H, Arima N, Ohtsubo H, Matsumoto T, Kukita T,Kawada H, Imaizumi R, Ozaki A, Matsushita K, Tei C. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia. Am J Hematol 2002;71:80-84.
  • 10Matsubayashi H, Takagaki S, Otsubo T, Iiri T, Kobayashi Y,Yokota T, Shichijo K, Iwafuchi M, Kijima H. Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor. J Gastroenterol 2002;37:863-867.

共引文献30

同被引文献29

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部